Eledon Pharmaceuticals, Inc. ELDN
1.97 USD -0.15 (-6.86%)
Regular-session close
1.94 -0.03 -1.52%
Pre-market · Nov 17, 8:07 AM ET
1.92 Day range 2.22
1.35 52-week range 4.49
- YTD
- +30.46%
- 1 year
- +11.93%
News
benzinga.com Eledon Pharma Q3 Adj. EPS $(0.16) Beats $(0.19) Estimate Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 23.81 percent increase over losses of…
globenewswire.com Eledon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Business Highlights Planned global Phase 3 LEGACY trial of tegoprubart in kidney transplantation remains on track to initiate in Q4 2026 FDA cleared the Company's IND application for a planned registrational path study…benzinga.com Eledon Pharma Reports Improved Quality Of Life And Reduced Symptom Burden With Tegoprubart In Kidney Transplant Patients At ASN Kidney Week 2026 Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom
